Dr. Kathy Miller, MD
Claim this profileIndiana University/Melvin and Bren Simon Cancer Center
Expert in Breast Cancer
Studies Cancer
17 reported clinical trials
55 drugs studied
About Kathy Miller, MD
Education:
- Earned an MD from Johns Hopkins University in 1991.
- Holds a BS from the University of Miami.
Experience:
- Completed a Residency in Internal Medicine at Johns Hopkins School of Medicine.
- Undertook a Fellowship in Hematology/Oncology at Indiana University School of Medicine, including a Chief Fellowship in 1997.
- Serves as a Professor of Oncology and Medicine, and the Ballvé Lantero Professor of Oncology at Indiana University School of Medicine.
- Holds the position of Associate Director of Clinical Research at the IU Simon Comprehensive Cancer Center.
- Actively involved as a Principal Investigator for multiple clinical trials, including those in the National Clinical Trials Network.
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 positive
ER positive
2Cancer
HER2 positive
BRAF
ER positive
Affiliated Hospitals
Clinical Trials Kathy Miller, MD is currently running
Pre-op Pembro + Radiation Therapy
for Breast Cancer
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. The names of the study interventions involved in this study are: * Radiation Therapy (RT) * Immunotherapy: Pembrolizumab (MK-3475) * Chemotherapies: * Paclitaxel * Doxorubicin (also called Adriamycin) * Cyclophosphamide * Carboplatin (optional, and in TN only) * Capecitabine (optional, and in TN only)
Recruiting1 award Phase 219 criteria
T-DM1 vs TH
for Breast Cancer
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Recruiting1 award Phase 2
More about Kathy Miller, MD
Clinical Trial Related8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Kathy Miller, MD has experience with
- Paclitaxel
- Avelumab
- Trastuzumab
- Capivasertib
- Pembrolizumab
- Palbociclib
Breakdown of trials Kathy Miller, MD has run
Breast Cancer
Cancer
Tumors
Gastric Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kathy Miller, MD specialize in?
Kathy Miller, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Kathy Miller, MD currently recruiting for clinical trials?
Yes, Kathy Miller, MD is currently recruiting for 6 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Kathy Miller, MD has studied deeply?
Yes, Kathy Miller, MD has studied treatments such as Paclitaxel, Avelumab, Trastuzumab.
What is the best way to schedule an appointment with Kathy Miller, MD?
Apply for one of the trials that Kathy Miller, MD is conducting.
What is the office address of Kathy Miller, MD?
The office of Kathy Miller, MD is located at: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University/Melvin and Bren Simon Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.